THE FUTURE OF DRUG RESEARCH AND MEDICAL DIAGNOSTICS
WEB SUMMIT 2015
EVOLUTION OF COMPUTER TECHNOLOGY
3
EVOLUTION OF COMPUTER TECHNOLOGY
EVOLUTION OF DRUG DISCOVERY TECHNOLOGY
5
EVOLUTION OF DRUG DISCOVERY TECHNOLOGY
THE PROBLEM
THE PROBLEM
Well plate technology has not changed in over 50 years
This 50 year-old technology is inefficient and comes with high capital costs
Complicated workflows
Need large testing volumes (loss of reagents)
Unstable (greater room for errors)
7
CURRENT SOLUTIONS ARE INADEQUATE
CURRENT SOLUTIONS ARE INADEQUATE
Costly Capex (smaller companies cannot afford the current technology)
Not scalable
Cannot handle high testing volumes
High margin for errors
Competitors believe these obstacles are just part of doing business. Neofluidics knows better, and we deliver on that knowledge by providing more efficient workflows through engineering-driven technology.
9
THE NEOFLUIDICS SOLUTION
Reduced sample volumes
= 99% cost savings!
Our lab-on-a-chip technology is in position to change the future of the field of drug discovery.
THE NEOFLUIDICS SOLUTION
No Capex (affordable for all companies,
large and small)
Compatibility with existing equipment
Error-free pipetting control
Enhanced quality of
testing
Ease of dilution On-site testing Fast results
A NEW PLATFORM FOR SCREENING TECHNOLOGY
A NEW PLATFORM FOR SCREENING TECHNOLOGY
Neofluidics products bring unprecedented efficiency to many different types of screening workflows by offering the following benefits:
Drastically reduces the volume needed to test compounds, not only allowing more tests to be run with rare compounds, such as with those from plant-derived sources that are available in extremely limited quantities, but also reducing reagent costs by up to 99%.
Does not require additional Capex, which enables smaller companies with limited budgets to undertake large-scale drug screening campaigns.
The simplicity and small footprint of the technology facilitates point of care diagnostics, increasing sensitivity of typical ELISA based screening.
13
A NEW PLATFORM FOR SCREENING TECHNOLOGY
Can screen small animal models (such as C.elegans and Zebrafish) in a high throughput fashion.
Can perform single-cell analysis with a series of microfluidic trapping chambers designed to capture single cells from a larger initial population.
Can facilitate cell culture and tissue organ modeling to test drug toxicity.
14
Zebrafish
THE MARKET
THE MARKET
New market research1 on the High Throughput Screening Market by Technology, Applications, and End Users:
R&D costs to discover a single drug have risen to $2.9-9 billion USD.2
In the past 50 years, the money spent on drug discovery has increased by 674%. The primary screening segment of
drug discovery is poised to grow at the highest compound annual growth rates in the industry.
$13.7
2013CurrentglobalHTSscreeningmarket
Billion
$19.6 Billion
2018(ProjectedCAGRof7.4%)
16
THE MARKET
17
1 www.marketsandmarkets.com 2
Diagnosing the decline in pharmaceutical R&D efficiency, Jack W. Scannell, Alex Blanckley, Helen Boldon & Brian Warrington, Nature Reviews Drug Discovery 11, 191-200 (March 2012)
THE NEOFLUIDICS STORY
Delivering on technology.
Neofluidics was born out of a doctoral thesis and has since disrupted a microfluidics product category that hasn’t changed in fifty years.
We challenge prevailing assumptions in fluid mechanics regarding complicated workflows, pipetting errors, and high screening costs.
Neofluidics develops next-generation tools and technology not only for the bioscience sector, but also in the military and petroleum sectors for enhanced microfluidics.
Our engineering-driven products add unprecedented convenience and efficiency to workflows, significantly reducing the costs of testing, culture, measurement, and analysis.
18
MARKET OPPORTUNITY
MARKET OPPORTUNITY
Audiences
Lab Screening Technicians
Single-Cell Genomics and Cancer Research
Scientists
Point-of-Care Diagnostics Providers
Pharmaceutical Scientists
Pharmaceutical Screening
Drug Screening
Cosmetic Screening
Pharmaceutical Research and Development
Academic Research and Development
Equine Banned Substance Testing
Sports Banned Substance Testing
Protein Solution Viscosity Characterization
20
MARKET OPPORTUNITY
Petroleum Engineers Military
Drilling Fluid Analysis
In-line Viscosity Measuring For Hydraulic Fluids and Fuel Condition
Future Target Audiences
21
MARKET OPPORTUNITY
Current Clients
22
HOW NEOFLUIDICS STACKS UP AGAINST THE COMPETITION
RESULTS CHART
24
MILESTONES
MILESTONES
MAY 2014
JUL 2014
AUG 2014
SEP 2014
AUG-NOV 2014
JAN 2015
MAY 2015
AUG 2015
MAR-SEP
2015
Oct 2015
DEC 2013
Neofluidics commercial feasibility through
NSF I-Corps
Winners of the Texas Techcelerator
incubator competition
Raised 200k from angel investors
Acquired exclusive IP
license from Texas Tech University
Set-up a clean lab for device
and application testing
Prototype R&D
completed
Neoplate product launch
Optimization of the Neoplate
based on feedback
Two proprietary patents held,
with 4 different product lines
Neoplate Prototype launch for field-testing to 30 customers
Proprietary patent for the company IP filed
and Neoplate prototype manufacturing initiated
DEC 2014 Application
testing started
26
MEET OUR TEAM
MEET OUR TEAM
Dr. Deepak Solomon
Chief Product Engineer
Dr. Nilesh Gupta
Chief Scientific Officer
Dr. Kevin Crawford
Chief Operating Officer
Charles E. Needham
Chief Marketing Officer
Alpesh Indulkar
Chief Manufacturing Officer
Dr. Rathnam Chagturu
Director of HTS at Stanford Research International (SRI)
Dr. Ali Khadim Hosseini
Professor, MIT
Dr. Barbara Smith
Professor, ASU
28